Characterising an Alternative Murine Model of Diabetic Cardiomyopathy

Mitchel Tate, Darnel Prakoso, Andrew M. Willis, Cheng Peng, Minh Deo, Cheng Xue Qin, Jesse L. Walsh, David M. Nash, Charles D. Cohen, Alex K. Rofe, Arpeeta Sharma, Helen Kiriazis, Daniel G. Donner, Judy B. De Haan, Anna M.D. Watson, Miles J. De Blasio, Rebecca H. Ritchie

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The increasing burden of heart failure globally can be partly attributed to the increased prevalence of diabetes, and the subsequent development of a distinct form of heart failure known as diabetic cardiomyopathy. Despite this, effective treatment options have remained elusive, due partly to the lack of an experimental model that adequately mimics human disease. In the current study, we combined three consecutive daily injections of low-dose streptozotocin with high-fat diet, in order to recapitulate the long-term complications of diabetes, with a specific focus on the diabetic heart. At 26 weeks of diabetes, several metabolic changes were observed including elevated blood glucose, glycated haemoglobin, plasma insulin and plasma C-peptide. Further analysis of organs commonly affected by diabetes revealed diabetic nephropathy, underlined by renal functional and structural abnormalities, as well as progressive liver damage. In addition, this protocol led to robust left ventricular diastolic dysfunction at 26 weeks with preserved systolic function, a key characteristic of patients with type 2 diabetes-induced cardiomyopathy. These observations corresponded with cardiac structural changes, namely an increase in myocardial fibrosis, as well as activation of several cardiac signalling pathways previously implicated in disease progression. It is hoped that development of an appropriate model will help to understand some the pathophysiological mechanisms underlying the accelerated progression of diabetic complications, leading ultimately to more efficacious treatment options.

Original languageEnglish
Article number1395
Number of pages15
JournalFrontiers in Physiology
Volume10
DOIs
Publication statusPublished - 14 Nov 2019

Keywords

  • cardiac
  • diabetes
  • diabetic cardiomyopathy
  • experimental model
  • type 2 diabetes

Cite this

Tate, Mitchel ; Prakoso, Darnel ; Willis, Andrew M. ; Peng, Cheng ; Deo, Minh ; Qin, Cheng Xue ; Walsh, Jesse L. ; Nash, David M. ; Cohen, Charles D. ; Rofe, Alex K. ; Sharma, Arpeeta ; Kiriazis, Helen ; Donner, Daniel G. ; De Haan, Judy B. ; Watson, Anna M.D. ; De Blasio, Miles J. ; Ritchie, Rebecca H. / Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. In: Frontiers in Physiology. 2019 ; Vol. 10.
@article{26290514bd1140b3bb636057d54ff2e5,
title = "Characterising an Alternative Murine Model of Diabetic Cardiomyopathy",
abstract = "The increasing burden of heart failure globally can be partly attributed to the increased prevalence of diabetes, and the subsequent development of a distinct form of heart failure known as diabetic cardiomyopathy. Despite this, effective treatment options have remained elusive, due partly to the lack of an experimental model that adequately mimics human disease. In the current study, we combined three consecutive daily injections of low-dose streptozotocin with high-fat diet, in order to recapitulate the long-term complications of diabetes, with a specific focus on the diabetic heart. At 26 weeks of diabetes, several metabolic changes were observed including elevated blood glucose, glycated haemoglobin, plasma insulin and plasma C-peptide. Further analysis of organs commonly affected by diabetes revealed diabetic nephropathy, underlined by renal functional and structural abnormalities, as well as progressive liver damage. In addition, this protocol led to robust left ventricular diastolic dysfunction at 26 weeks with preserved systolic function, a key characteristic of patients with type 2 diabetes-induced cardiomyopathy. These observations corresponded with cardiac structural changes, namely an increase in myocardial fibrosis, as well as activation of several cardiac signalling pathways previously implicated in disease progression. It is hoped that development of an appropriate model will help to understand some the pathophysiological mechanisms underlying the accelerated progression of diabetic complications, leading ultimately to more efficacious treatment options.",
keywords = "cardiac, diabetes, diabetic cardiomyopathy, experimental model, type 2 diabetes",
author = "Mitchel Tate and Darnel Prakoso and Willis, {Andrew M.} and Cheng Peng and Minh Deo and Qin, {Cheng Xue} and Walsh, {Jesse L.} and Nash, {David M.} and Cohen, {Charles D.} and Rofe, {Alex K.} and Arpeeta Sharma and Helen Kiriazis and Donner, {Daniel G.} and {De Haan}, {Judy B.} and Watson, {Anna M.D.} and {De Blasio}, {Miles J.} and Ritchie, {Rebecca H.}",
year = "2019",
month = "11",
day = "14",
doi = "10.3389/fphys.2019.01395",
language = "English",
volume = "10",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

Tate, M, Prakoso, D, Willis, AM, Peng, C, Deo, M, Qin, CX, Walsh, JL, Nash, DM, Cohen, CD, Rofe, AK, Sharma, A, Kiriazis, H, Donner, DG, De Haan, JB, Watson, AMD, De Blasio, MJ & Ritchie, RH 2019, 'Characterising an Alternative Murine Model of Diabetic Cardiomyopathy', Frontiers in Physiology, vol. 10, 1395. https://doi.org/10.3389/fphys.2019.01395

Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. / Tate, Mitchel; Prakoso, Darnel; Willis, Andrew M.; Peng, Cheng; Deo, Minh; Qin, Cheng Xue; Walsh, Jesse L.; Nash, David M.; Cohen, Charles D.; Rofe, Alex K.; Sharma, Arpeeta; Kiriazis, Helen; Donner, Daniel G.; De Haan, Judy B.; Watson, Anna M.D.; De Blasio, Miles J.; Ritchie, Rebecca H.

In: Frontiers in Physiology, Vol. 10, 1395, 14.11.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Characterising an Alternative Murine Model of Diabetic Cardiomyopathy

AU - Tate, Mitchel

AU - Prakoso, Darnel

AU - Willis, Andrew M.

AU - Peng, Cheng

AU - Deo, Minh

AU - Qin, Cheng Xue

AU - Walsh, Jesse L.

AU - Nash, David M.

AU - Cohen, Charles D.

AU - Rofe, Alex K.

AU - Sharma, Arpeeta

AU - Kiriazis, Helen

AU - Donner, Daniel G.

AU - De Haan, Judy B.

AU - Watson, Anna M.D.

AU - De Blasio, Miles J.

AU - Ritchie, Rebecca H.

PY - 2019/11/14

Y1 - 2019/11/14

N2 - The increasing burden of heart failure globally can be partly attributed to the increased prevalence of diabetes, and the subsequent development of a distinct form of heart failure known as diabetic cardiomyopathy. Despite this, effective treatment options have remained elusive, due partly to the lack of an experimental model that adequately mimics human disease. In the current study, we combined three consecutive daily injections of low-dose streptozotocin with high-fat diet, in order to recapitulate the long-term complications of diabetes, with a specific focus on the diabetic heart. At 26 weeks of diabetes, several metabolic changes were observed including elevated blood glucose, glycated haemoglobin, plasma insulin and plasma C-peptide. Further analysis of organs commonly affected by diabetes revealed diabetic nephropathy, underlined by renal functional and structural abnormalities, as well as progressive liver damage. In addition, this protocol led to robust left ventricular diastolic dysfunction at 26 weeks with preserved systolic function, a key characteristic of patients with type 2 diabetes-induced cardiomyopathy. These observations corresponded with cardiac structural changes, namely an increase in myocardial fibrosis, as well as activation of several cardiac signalling pathways previously implicated in disease progression. It is hoped that development of an appropriate model will help to understand some the pathophysiological mechanisms underlying the accelerated progression of diabetic complications, leading ultimately to more efficacious treatment options.

AB - The increasing burden of heart failure globally can be partly attributed to the increased prevalence of diabetes, and the subsequent development of a distinct form of heart failure known as diabetic cardiomyopathy. Despite this, effective treatment options have remained elusive, due partly to the lack of an experimental model that adequately mimics human disease. In the current study, we combined three consecutive daily injections of low-dose streptozotocin with high-fat diet, in order to recapitulate the long-term complications of diabetes, with a specific focus on the diabetic heart. At 26 weeks of diabetes, several metabolic changes were observed including elevated blood glucose, glycated haemoglobin, plasma insulin and plasma C-peptide. Further analysis of organs commonly affected by diabetes revealed diabetic nephropathy, underlined by renal functional and structural abnormalities, as well as progressive liver damage. In addition, this protocol led to robust left ventricular diastolic dysfunction at 26 weeks with preserved systolic function, a key characteristic of patients with type 2 diabetes-induced cardiomyopathy. These observations corresponded with cardiac structural changes, namely an increase in myocardial fibrosis, as well as activation of several cardiac signalling pathways previously implicated in disease progression. It is hoped that development of an appropriate model will help to understand some the pathophysiological mechanisms underlying the accelerated progression of diabetic complications, leading ultimately to more efficacious treatment options.

KW - cardiac

KW - diabetes

KW - diabetic cardiomyopathy

KW - experimental model

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85076006941&partnerID=8YFLogxK

U2 - 10.3389/fphys.2019.01395

DO - 10.3389/fphys.2019.01395

M3 - Article

AN - SCOPUS:85076006941

VL - 10

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - 1395

ER -